NCT02137083View on ClinicalTrials.gov

A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Docetaxel

75mg/m2 D2 every 21 days

DRUG

Fulvestrant

500mg D1, D15, D29, D57, every 28 days later

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT02137083 - A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter